Nr 4, 2019: Matsmältning

Spännande smaker med god näring, Pia Andrea, hälsoskribent

Människans artriktiga kost, Jonas Bergqvist, leg sjukgymnast, utbildare

1. Fumagalli Matteo et al; Greenlandic Inuit show genetic signatures of diet and climate adaptation; Science 18 September 2015: Vol. 349 no. 6254 pp. 1343-1347

2. Roseboom TJ; Effects of prenatal exposure to the Dutch famine on adult disease in later life: an overview; Molecular and Cellular Endocrinology 185 (2001) 93–98

3. Henry AG, Brooks AS, Piperno DR. Microfossils in calculus demonstrate consumption of plants and cooked foods in Neanderthal diets. Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):486-91

Så påverkas din matsmältning av stress, Mikaela Bjerring, näringsterapeut, hälsoskribent

1. Effects of occupational stress on the gastrointestinal tract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3829457/

2. The Effect of Emotional Stress and Depression on the Prevalence of Digestive Diseases: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398234/

3. The bowel and beyond: the enteric nervous system in neurological disorders: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5005185/

4. Stress and the sensitive gut: https://www.health.harvard.edu/newsletter_article/stress-and-the-sensitive-gut

5. Enzyme Science: https://enzyscience.com/pages/enzyme-faq

6. Neural and Hormonal Regulation of Pancreatic Secretion: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2838392/

7. Stress, Food, and Inflammation: Psychoneuroimmunology and Nutrition at the Cutting Edge: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2868080/

8. Introduction to the human gut microbiota: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433529/

9. Gut microbiota functions: metabolism of nutrients and other food components: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847071/

10. Stress & the gut-brain axis: Regulation by the microbiome: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736941/

11. Stress at the intestinal surface: catecholamines and mucosa-bacteria interactions: https://www.ncbi.nlm.nih.gov/pubmed/20941511

12. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367209/

13. Stress and the gut: Pathophysiology, clinic consequences, diagnostic approach and treatment option http://www.jpp.krakow.pl/journal/archive/12_11/pdf/591_12_11_article.pdf

14. Stressor Exposure Disrupts Commensal Microbial Populations in the Intestines and Leads to Increased Colonization by Citrobacter rodentium: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2849416/

15. Exposure to a Social Stressor Alters the Structure of the Intestinal Microbiota: Implications for Stressor-Induced Immunomodulation: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3039072/

16. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options: https://www.ncbi.nlm.nih.gov/pubmed/22314561

17. Stress and the gut: Pathophysiology, clinic consequences, diagnostic approach and treatment option http://www.jpp.krakow.pl/journal/archive/12_11/pdf/591_12_11_article.pdf

18. How Stress Contributes to SIBO: https://kresserinstitute.com/how-stress-contributes-to-sibo/

19. Gut Pathogens: https://gutpathogens.biomedcentral.com/articles/10.1186/1757-4749-3-1

PPI – medicin med sur eftersmak, Linus Mårtensson, leg läkare, specialist i allmänmedicin

1. Agréus MS. Sjukdomar i matstrupe, magsäck och tolvfingertarm | Läkemedelsboken [Internet]. [cited 2019 Mar 27]. Available from: https://lakemedelsboken.se/kapitel/mage-tarm/sjukdomar_i_matstrupe_magsack_och_tolvfingertarm.html

2. Statistik om läkemedel 2017 [Internet]. [cited 2019 Mar 27]. Available from: https://www.socialstyrelsen.se/publikationer2018/2018-4-7

3. Lindström E, Chen D, Norlén P, Andersson K, Håkanson R. Control of gastric acid secretion:the gastrin-ECL cell-parietal cell axis. Comp Biochem Physiol, Part A Mol Integr Physiol. 2001 Mar;128(3):505–14.

4. Smith JL. The role of gastric acid in preventing foodborne disease and how bacteria overcome acid conditions. J Food Prot. 2003 Jul;66(7):1292–303.

5. Tennant SM, Hartland EL, Phumoonna T, Lyras D, Rood JI, Robins-Browne RM, et al. Influence of gastric acid on susceptibility to infection with ingested bacterial pathogens. Infect Immun. 2008 Feb;76(2):639–45.

6. Zhu H, Hart CA, Sales D, Roberts NB. Bacterial killing in gastric juice–effect of pH and pepsin on Escherichia coli and Helicobacter pylori. J Med Microbiol. 2006 Sep;55(Pt 9):1265–70.

7. Parasa S, Sharma P. Complications of gastro-oesophageal reflux disease. Best Pract Res Clin Gastroenterol. 2013 Jun;27(3):433–42.

8. Miwa H, Kondo T, Oshima T, Fukui H, Tomita T, Watari J. Esophageal sensation and esophageal hypersensitivity – overview from bench to bedside. J Neurogastroenterol Motil. 2010 Oct 30;16(4):353–62.

9. Sharp GS, Fister HW. The diagnosis and treatment of achlorhydria: ten-year study. J Am Geriatr Soc. 1967 Aug;15(8):786–91.

10. Boeckxstaens GE. The lower oesophageal sphincter. Neurogastroenterol Motil. 2005 Jun;17 Suppl 1:13–21.

11. Diamant NE. Pathophysiology of gastroesophageal reflux disease. GI Motility online. 2006 May 16;

12. Holloway RH, Dent J. Pathophysiology of gastroesophageal reflux. Lower esophageal sphincter dysfunction in gastroesophageal reflux disease. Gastroenterol Clin North Am. 1990 Sep;19(3):517–35.

13. Navarro-Rodriguez T, Hashimoto CL, Carrilho FJ, Strauss E, Laudanna AA, Moraes-Filho JPP. Reduction of abdominal pressure in patients with ascites reduces gastroesophageal reflux. Dis Esophagus. 2003 Jun 1;16(2):77–82.

14. The Real Reasons for GERD: What You Need To Know | Sepalika [Internet]. [cited 2019 Mar 30]. Available from: https://www.sepalika.com/gerd/why-gerd-happens/

15. Rumessen JJ. Hydrogen and methane breath tests for evaluation of resistant carbohydrates. Eur J Clin Nutr. 1992 Oct;46 Suppl 2:S77-90.

16. Nasser SC, Slim M, Nassif JG, Nasser SM. Influence of proton pump inhibitors on gastritis diagnosis and pathologic gastric changes. World J Gastroenterol. 2015 Apr 21;21(15):4599–606.

17. Li Z, Wu C, Li L, Wang Z, Xie H, He X, et al. Effect of long-term proton pump inhibitor administration on gastric mucosal atrophy: A meta-analysis. Saudi J Gastroenterol. 2017 Aug;23(4):222–8.

18. Marcuard SP, Albernaz L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med. 1994 Feb 1;120(3):211–5.

19. Howden CW. Vitamin B12 levels during prolonged treatment with proton pump inhibitors. J Clin Gastroenterol. 2000 Jan;30(1):29–33.

20. Jacobs A, Lawrie JH, Entwistle CC, Campbell H. Gastric acid secretion in chronic iron-deficiency anaemia. Lancet. 1966 Jul;288(7456):190–2.

21. Bezwoda W, Charlton R, Bothwell T, Torrance J, Mayet F. The importance of gastric hydrochloric acid in the absorption of nonheme food iron. The Journal of Laboratory and Clinical Medicine [Internet]. 1978 Jul 1 [cited 2019 Mar 27];92(1):108–16. Available from: https://www.translationalres.com/article/0022-2143(78)90074-4/abstract

22. Henderson LM, Brewer GJ, Dressman JB, Swidan SZ, DuRoss DJ, Adair CH, et al. Effect of intragastric pH on the absorption of oral zinc acetate and zinc oxide in young healthy volunteers. JPEN J Parenter Enteral Nutr. 1995 Oct;19(5):393–7.

23. Champagne ET. Low gastric hydrochloric acid secretion and mineral bioavailability. Adv Exp Med Biol. 1989;249:173–84.

24. Omeprazol Apofri – FASS Vårdpersonal [Internet]. [cited 2019 Mar 30]. Available from: https://www.fass.se/LIF/product?userType=0&nplId=20100227000013

25. Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2010 Jun;8(6):504–8.

26. Theisen J, Nehra D, Citron D, Johansson J, Hagen JA, Crookes PF, et al. Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. J Gastrointest Surg. 4(1):50–4.

27. Pounder RE, Ng D. The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther. 1995;9 Suppl 2:33–9.

28. El-Omar EM, Oien K, El-Nujumi A, Gillen D, Wirz A, Dahill S, et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology. 1997 Jul;113(1):15–24.

29. Vannella L, Lahner E, Annibale B. Risk for gastric neoplasias in patients with chronic atrophic gastritis: a critical reappraisal. World J Gastroenterol. 2012 Mar 28;18(12):1279–85.

30. Cheung DY. Atrophic gastritis increases the risk of gastric cancer in asymptomatic population in korea. Gut Liver. 2017 Sep 15;11(5):575–6.

31. Brusselaers N, Wahlin K, Engstrand L, Lagergren J. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open. 2017 Oct 30;7(10):e017739.

32. Mattsson JP, Väänänen K, Wallmark B, Lorentzon P. Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases. Biochim Biophys Acta. 1991 Jun 18;1065(2):261–8.

33. Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol. 2016 Oct;27(10):3153–63.

34. Shah NH, LePendu P, Bauer-Mehren A, Ghebremariam YT, Iyer SV, Marcus J, et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS ONE. 2015 Jun 10;10(6):e0124653.

35. Charlot M, Grove EL, Hansen PR, Olesen JB, Ahlehoff O, Selmer C, et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ. 2011 May 11;342:d2690.

36. Charlot M, Ahlehoff O, Norgaard ML, Jørgensen CH, Sørensen R, Abildstrøm SZ, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med. 2010 Sep 21;153(6):378–86.

37. Abstract 18462: Proton Pump Inhibitor Use Increases the Associated Risk of First-Time Ischemic Stroke. A Nationwide Cohort Study | Circulation. Circulation.

38. Lin SM, Yang SH, Liang CC, Huang HK. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study. Osteoporos Int. 2018;29(1):153–62.

39. Gomm W, von Holt K, Thomé F, Broich K, Maier W, Fink A, et al. Association of proton pump inhibitors with risk of dementia: A pharmacoepidemiological claims data analysis. JAMA Neurol. 2016 Apr;73(4):410–6.

40. Akter S, Hassan MR, Shahriar M, Akter N, Abbas MG, Bhuiyan MA. Cognitive impact after short-term exposure to different proton pump inhibitors: assessment using CANTAB software. Alzheimers Res Ther. 2015 Dec 27;7:79.

41. Laudisio A, Antonelli Incalzi R, Gemma A, Giovannini S, Lo Monaco MR, Vetrano DL, et al. Use of proton-pump inhibitors is associated with depression: a population-based study. Int Psychogeriatr. 2018;30(1):153–9.

42. Huang W-S, Bai Y-M, Hsu J-W, Huang K-L, Tsai C-F, Su T-P, et al. Use of Proton Pump Inhibitors and Risk of Major Depressive Disorder: A Nationwide Population-Based Study. Psychother Psychosom. 2018 Jan 6;87(1):62–4.

43. Fossmark R, Johnsen G, Johanessen E, Waldum HL. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther. 2005 Jan 15;21(2):149–54.

44. Rebound Symptoms After Stopping PPIs [Internet]. [cited 2019 Mar 30]. Available from: https://www.medscape.com/viewarticle/709084_1

45. Niv Y. Gradual cessation of proton pump inhibitor (PPI) treatment may prevent rebound acid secretion, measured by the alkaline tide method, in dyspepsia and reflux patients. Med Hypotheses. 2011 Sep;77(3):451–2.

46. Haastrup P, Paulsen MS, Begtrup LM, Hansen JM, Jarbøl DE. Strategies for discontinuation of proton pump inhibitors: a systematic review. Fam Pract. 2014 Dec;31(6):625–30.

47. Targownik L. Discontinuing Long-Term PPI Therapy: Why, With Whom, and How? Am J Gastroenterol. 2018 Apr;113(4):519–28.

48. Ishii Y. Mechanism of gastric antisecretory activity of a new fraction of licorice root (fm100). JpnJPharmacol. 1970;20(1):71–9.

49. Ishii Y, Fujii Y. Effects of Fm100, a fraction of licorice root, on serum gastrin concentration in rats and dogs. JpnJPharmacol. 1982;32(1):23–7.

50. Kines K, Krupczak T. Nutritional interventions for gastroesophageal reflux, irritable bowel syndrome, and hypochlorhydria: A case report. Integr Med (Encinitas). 2016 Aug;15(4):49–53.

51. Kinoshita Y, Ishimura N, Ishihara S. Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use. J Neurogastroenterol Motil. 2018 Apr 30;24(2):182–96.

Tillbaka